A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-27

Study Completion Date

2025-02-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is open to adults with plaque psoriasis. The main purpose of this study is to find out whether people with plaque psoriasis can tolerate a medicine called BI 765250. Another purpose is to check whether BI 765250 can improve participants' skin condition.

Participants are divided into 5 groups. Each group gets a different dose of BI 765250 or placebo as an infusion or injection for 12 weeks. Placebo infusions and injections look like BI 765250 but do not contain any medicine. It is decided by chance, who gets BI 765250 and who gets placebo. During the first 2 weeks, participants get the study medicine as an infusion into a vein once a week. Afterwards, they get the study medicine as an injection under the skin every 2 or 4 weeks. In total, every participant gets up to 5 injections.

Participants are in the study for about 8 months. During this time, they visit the study site 23 times. On 2 of the visits, participants stay overnight at the study site, once for 2 nights and once for 1 night. The doctors collect information on any health problems of the participants. They also regularly check participants' skin condition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

NCT03635099

Psoriasis

COMPLETED PHASE2

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

NCT03835481

Psoriasis

TERMINATED PHASE2

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

NCT05223868

Plaque Psoriasis

COMPLETED PHASE2

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

NCT01577550

Psoriasis

COMPLETED PHASE1

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

NCT05357755

Plaque Psoriasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 765250 very low dose group

Group Type EXPERIMENTAL

BI 765250

Intervention Type DRUG

BI 765250

Placebo group

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo

BI 765250 low dose group

Group Type EXPERIMENTAL

BI 765250

Intervention Type DRUG

BI 765250

BI 765250 medium dose group

Group Type EXPERIMENTAL

BI 765250

Intervention Type DRUG

BI 765250

BI 765250 high dose group

Group Type EXPERIMENTAL

BI 765250

Intervention Type DRUG

BI 765250

BI 765250 very high dose group

Group Type EXPERIMENTAL

BI 765250

Intervention Type DRUG

BI 765250

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 765250

Intervention Type DRUG

Placebo

placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female participants of non-childbearing potential and male participants
* Age 18 to 75 years (both inclusive) at the time of informed consent
* Diagnosis of chronic plaque psoriasis for at least 6 months prior to randomisation, as confirmed by their medical record or history
* Moderate to severe plaque psoriasis, as defined by:

* Body surface area (BSA) ≥5% and \<30%
* Static Physician's Global Assessment (sPGA) ≥3
* Target lesions suitable for skin biopsy
* Body mass index (BMI) \<35 kg/m2
* Male participants able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use is provided in the participant information
* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

Exclusion Criteria

* Non-plaque forms of psoriasis, current drug-induced psoriasis, or active ongoing inflammatory diseases other than psoriasis that might confound trial evaluations
* Major surgery (major according to the investigator's assessment, e.g. hip replacement) performed within 16 weeks prior to randomisation or planned during the trial (i.e. until the End of Study Visit)
* Women of childbearing potential (WOCBP), breastfeeding women, and men unwilling or unable to use highly effective methods of birth control
* Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening
* Live or attenuated vaccination ≤6 weeks prior to randomisation, or any plan to receive a live vaccination during the conduct of this trial until the End of Treatment Visit
* Participants who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
* Hepatic/renal impairment:

* Hepatic impairment defined as \>3-fold Upper Limit of Normal (ULN) elevation in AST or ALT or alkaline phosphatase, or \>2-fold ULN elevation in total bilirubin. Trial participants with Gilbert´s syndrome can be included unless total bilirubin elevation was \>5-fold ULN at screening visit and unless proportions of bilirubin fractions are inconsistent with diagnosis of Gilbert´s syndrome.
* Renal impairment defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No